Myriad reloaded and ready for the next round?
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › fagfællebedømt
Standard
Myriad reloaded and ready for the next round? / Minssen, Timo; Schwartz, Robert.
I: Queen Mary Journal of Intellectual Property, Bind Vol 3, Nr. 1, 01.2013, s. 70-80.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Myriad reloaded and ready for the next round?
AU - Minssen, Timo
AU - Schwartz, Robert
N1 - Valideret ud fra tilgængelige oplysninger på Edgar online. Yderligere oplysninger i titelfeltet:"The Association for Molecular Pathology v U.S.P.T.O., 689 F.3d 1303 (Fed. Cir. 2012)."
PY - 2013/1
Y1 - 2013/1
N2 - In March 2011 the Supreme Court issued its Prometheus opinion and granted certiorari, reversed and remanded Myriad I for consideration in light of Prometheus. In August 2012 the Myriad II decision was issued. The panel in Myriad II repeated most of their separate Myriad I opinions. Myriad déjà vu looked much Myriad I with panel members agreeing that Prometheus did not control the composition of matter claims. The opinions differed on whether composition claims were to be analyzed from a chemical, structural or carrier of information standpoint with respect to laws of nature. The rationales used such rhetorical metaphors as cleaving, baseball bats, magic microscopes, extracted kidneys, slabs of marble or marble statues, the Sistine Chapel, and whether cells were “transformed” molecules or “carriers of information". The differing evaluations of patent-eligibility and the cursory manner in which they addressed the Supreme Court’s GVR mandate may well guarantee a return appearance before the Supreme Court or, at a minimum, en banc review by the Circuit
AB - In March 2011 the Supreme Court issued its Prometheus opinion and granted certiorari, reversed and remanded Myriad I for consideration in light of Prometheus. In August 2012 the Myriad II decision was issued. The panel in Myriad II repeated most of their separate Myriad I opinions. Myriad déjà vu looked much Myriad I with panel members agreeing that Prometheus did not control the composition of matter claims. The opinions differed on whether composition claims were to be analyzed from a chemical, structural or carrier of information standpoint with respect to laws of nature. The rationales used such rhetorical metaphors as cleaving, baseball bats, magic microscopes, extracted kidneys, slabs of marble or marble statues, the Sistine Chapel, and whether cells were “transformed” molecules or “carriers of information". The differing evaluations of patent-eligibility and the cursory manner in which they addressed the Supreme Court’s GVR mandate may well guarantee a return appearance before the Supreme Court or, at a minimum, en banc review by the Circuit
KW - Faculty of Law
KW - US patents, gene patents, diagnostic methods, personalized medicine, biotech
M3 - Journal article
VL - Vol 3
SP - 70
EP - 80
JO - Queen Mary Journal of Intellectual Property
JF - Queen Mary Journal of Intellectual Property
SN - 2045-9807
IS - 1
ER -
ID: 40874446